EMA400,
EMA401,
Olodanrigan,
PD-126055 free acid,
1316755-16-4,
EMA401,
EMA-401,
UNII-P0FN522VTO,
P0FN522VTO,
CHEMBL34124,
PD-126055,
(S)-5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid,
EMA401; Olodanrigan,
Olodanrigan(EMA401),
Olodanrigan [WHO-DD],
[S]-enantiomer of EMA400,
Olodanrigan; PD-126055,
SCHEMBL421411,
GTPL8374,
EX-A2623,
ZINC1483494,
[S]-enantiomer of PD-126,055,
BDBM50049182,
MFCD28502251,
CS-5781,
SB17387,
AS-53290,
HY-13106,
J3.529.092C,
Olodanrigan,EMA 401,EMA-401,EMA401,1418274-28-8,
(3S)-2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid,
(S)-5-Benzyloxy-2-diphenylacetyl-6-methoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid,
3-Isoquinolinecarboxylic acid, 2-(2,2-diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-, (3S)-,
D0O0JP,
3-Isoquinolinecarboxylicacid,
CID9937291,
y0102-032352,
Neuropathic pain targeting small molecules (postherpetic neuralgia), Spinifex,
2-(2,2-diphenylacetyl)-6-methoxy-5-phenylmethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic Acid,